<DOC>
	<DOCNO>NCT00588146</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability pegylated interferon alpha-2b ( PEG-Intron ) patient severe complication related Hereditary hemorrhagic telangiectasia ( HHT ) . Funding Source - FDA Office Orphan Products Development ( OOPD )</brief_summary>
	<brief_title>Phase 2 Study PEG-Intron Hereditary Hemorrhagic Telangiectasia</brief_title>
	<detailed_description>The objective study evaluate safety tolerability pegylated interferon alpha-2b ( PEG-Intron ) patient severe complication related Hereditary Hemorrhagic Telangiectasia ( HHT ) . Participants randomize treatment arm control arm cross alternate arm 6 month remainder 12-month study . Study treatment consist weekly subcutaneous injection pegylated interferon alpha-2b ( PEG-Intron ) , 1 microgram/kilogram/week . Adverse event well monitor treatment toxicity follow state protocol . Adverse event grade accord Modified NCI Common Toxicity Criteria . After every five participant complete one month treatment , independent data safety monitor board review adverse event .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Anoxia</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1 . Definite diagnosis HHT clinical criterion genetic diagnosis . For clinical diagnosis , 3 4 follow criteria1 must present : 1 . Epistaxis : spontaneous , recurrent 2 . Telangiectases : multiple characteristic site 3 . Visceral lesion include telangiectases and/or arteriovenous malformation ( AVM ) ( pulmonary , hepatic , gastrointestinal , cerebral , spinal ) 4 . Family history first degree relative HHT 2 . Transfusiondependent anemia HHTrelated bleeding ( epistaxis nasal mucosal telangiectases gastrointestinal bleed gastrointestinal telangiectases ) define hemoglobin ( Hb ) &lt; 9g/dL transfusion least one unit pack red blood cell within past 6 month Hb &lt; 11g/dL female &lt; 13g/dL male transfusion least 5 unit blood within past 6 month . Patients must stable dose iron intolerant iron . Patients must fail traditional treatment option . 3 . Clinically stable outpatient 4 . Able willing return outpatient visit 5 . Ability perform subcutaneous injection 6 . Adult ( Age 18 70 year ) 7 . Presence follow laboratory result entry : 1 . White blood cell count ≥ 2000/mm^3 2 . Neutrophil count ≥ 1000/mm^3 3 . Platelet count ≥ 80,000/mm^3 4 . Thyroid stimulate hormone within normal limit ( Minimal abnormality sensitive thyroid stimulate hormone may allow provide free thyroxin normal patient clinically euthyroid ) 8 . Negative pregnancy test enrollment , applicable 9 . If participant sexually active woman childbearing potential , evidence practice adequate contraception treatment period . Adequate contraception include use intrauterine device , oral contraceptive , progesterone implant rod , medroxyprogesterone acetate , surgical sterilization , barrier method ( diaphragm + spermicide ) , monogamous relationship male partner vasectomy use condom + spermicide birth control method acceptable study physician . Participants and/or partner must agree continue use adequate contraception least 6 month follow completion treatment . 10 . Written inform consent specific protocol obtain prior entry 11 . Patients agree take study medication direct follow study relate procedure conclusion protocol participation 12 . Hepatic involvement HHT characterize high output heart failure due hepatic vascular malformation ( symptom heart failure include edema , ascites , S3 gallop , orthopnea , jugular venous pressure &gt; 10 cm H_2O ) plus cardiac index ( CI ) measure right heart catheterization &gt; 4.4 L/min/m^2 . Patients must fail traditional treatment option . 13 . Computed tomography scanning ( CT ) liver document vascular abnormality consistent HHT 14 . ChildPugh category A 15 . Diffuse pulmonary telangiectases AVMs document pulmonary angiography amenable treatment embolization technique . Patients must fail traditional treatment option . 16 . Positive contrast echocardiography document right left intrapulmonary shunt 17 . Resting exerciseinduced hypoxemia define partial pressure oxygen ( PaO_2 ) &lt; 70 mmHg rest oxygen saturation ( SpO_2 ) &lt; 85 % exercise . 1 . Anemia cause due HHTrelated bleeding 2 . Hypersensitivity PEGIntron component product 3 . Decompensated liver disease 1 . Chronic active Hepatitis B infection 2 . ChildPugh category B C 4 . History severe psychiatric disease 1 . Prior suicide attempt 2 . Hospitalization psychiatric disease 3 . Period disability due psychiatric disease 4 . Current episode moderate severe depression responsive treatment 5 . History immunologically mediate disease 1 . Inflammatory bowel disease 2 . Idiopathic thrombocytopenic purpura 3 . Systemic lupus erythematosus 4 . Autoimmune hemolytic anemia 5 . Scleroderma 6 . Sarcoidosis 7 . Multiple sclerosis 8 . Severe psoriasis 9 . Clinical evidence rheumatoid arthritis 10 . Autoimmune hepatitis 6 . History clinically significant cardiovascular disease 1 . Positive stress test 2 . Clinically significant arrhythmia 3 . Congestive heart failure 4 . Uncontrolled hypertension 5 . Coronary artery bypass surgery within 24 week prior entry 6 . Angina pectoris myocardial infarction within 1 year prior entry 7 . Seizure disorder uncontrolled anticonvulsant ( within last 12 month ) 8 . History thyroid disease poorly control prescribed medication 9 . History evidence retinopathy 10 . Patients chronic anticoagulation 11 . History chronic renal insufficiency ( creatinine &gt; 2.5 mg/dL ) 12 . Patients receive investigational drug within 24 week treatment assignment 13 . History evidence severe illness comorbid condition would make patient unsuitable participation research protocol 14 . Liver dysfunction cause due HHT ( chronic active hepatitis B infection , hepatitis C infection , alcoholic cirrhosis , etc . ) 15 . Cardiac index &lt; 4.4 L/min/m^2 16 . Pulmonary AVMs feeding artery &gt; 3 mm diameter amenable embolization technique 17 . Other pulmonary disease cause hypoxemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>anemia</keyword>
	<keyword>HHT</keyword>
	<keyword>Liver disease</keyword>
	<keyword>Hypoxemia</keyword>
	<keyword>Iron deficiency anemia</keyword>
	<keyword>Liver disease high cardiac output</keyword>
	<keyword>Diffuse pulmonary AVMs hypoxemia</keyword>
</DOC>